Bridge Biotherapeutics Valuation
| 288330 Stock | KRW 4,050 445.00 9.90% |
At this time, the firm appears to be overvalued. Bridge Biotherapeutics shows a prevailing Real Value of W3488.1 per share. The current price of the firm is W4050.0. Our model approximates the value of Bridge Biotherapeutics from analyzing the firm fundamentals such as Revenue of 1.92 B, return on equity of -75.4, and Shares Owned By Insiders of 30.27 % as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Bridge Biotherapeutics' price fluctuation is very steady at this time. Calculation of the real value of Bridge Biotherapeutics is based on 3 months time horizon. Increasing Bridge Biotherapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Bridge Biotherapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Bridge Stock. However, Bridge Biotherapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 4050.0 | Real 3488.1 | Hype 4050.0 |
The real value of Bridge Stock, also known as its intrinsic value, is the underlying worth of Bridge Biotherapeutics Company, which is reflected in its stock price. It is based on Bridge Biotherapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Bridge Biotherapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Bridge Biotherapeutics helps investors to forecast how Bridge stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Bridge Biotherapeutics more accurately as focusing exclusively on Bridge Biotherapeutics' fundamentals will not take into account other important factors: Bridge Biotherapeutics Total Value Analysis
Bridge Biotherapeutics is presently forecasted to have takeover price of 29.26 B with market capitalization of 217.07 B, debt of 53.63 M, and cash on hands of 8.2 B. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Bridge Biotherapeutics fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
29.26 B | 217.07 B | 53.63 M | 8.2 B |
Bridge Biotherapeutics Investor Information
About 30.0% of the company shares are owned by insiders or employees . The company had not issued any dividends in recent years. Bridge Biotherapeutics had 1:1 split on the 29th of July 2024. Based on the key indicators related to Bridge Biotherapeutics' liquidity, profitability, solvency, and operating efficiency, Bridge Biotherapeutics is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.Bridge Biotherapeutics Asset Utilization
The concept of asset utilization usually refers to the revenue earned for every dollar of assets a company currently reports. The current return on assets of Bridge suggests not a very effective usage of assets in December.Bridge Biotherapeutics Ownership Allocation
The market capitalization of Bridge Biotherapeutics is W217.07 Billion. Bridge Biotherapeutics retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.Bridge Biotherapeutics Profitability Analysis
The company reported the revenue of 1.92 B. Net Loss for the year was (26.28 B) with loss before overhead, payroll, taxes, and interest of (1.12 B).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Bridge Biotherapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Bridge Biotherapeutics and how it compares across the competition.
About Bridge Biotherapeutics Valuation
The stock valuation mechanism determines Bridge Biotherapeutics' current worth on a weekly basis. Our valuation model uses a comparative analysis of Bridge Biotherapeutics. We calculate exposure to Bridge Biotherapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Bridge Biotherapeutics's related companies.Bridge Biotherapeutics, Inc., a clinical stage biotech company, engages in the development of therapeutics for the treatment of ulcerative colitis, fibrotic diseases, and cancers worldwide. The company was founded in 2015 and is headquartered in Seongnam, Korea. BRIDGE BIOTHERAPEUTICS is traded on Korean Securities Dealers Automated Quotations in South Korea.
8 Steps to conduct Bridge Biotherapeutics' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Bridge Biotherapeutics' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Bridge Biotherapeutics' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Bridge Biotherapeutics' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Bridge Biotherapeutics' revenue streams: Identify Bridge Biotherapeutics' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Bridge Biotherapeutics' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Bridge Biotherapeutics' growth potential: Evaluate Bridge Biotherapeutics' management, business model, and growth potential.
- Determine Bridge Biotherapeutics' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Bridge Biotherapeutics' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for Bridge Stock analysis
When running Bridge Biotherapeutics' price analysis, check to measure Bridge Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bridge Biotherapeutics is operating at the current time. Most of Bridge Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Bridge Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bridge Biotherapeutics' price. Additionally, you may evaluate how the addition of Bridge Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |